Diligence memo · auto-generated · as of July 2, 2026

Toltec Pharmaceuticals, Llc

Toltec Pharmaceuticals, Llc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Toltec Pharmaceuticals, Llc operates in Pharmaceuticals, based in CHICAGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Toltec Pharmaceuticals, Llc has raised $10M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $4.0M on 2010-12-31.

Most recent recorded round closed around 2010-12-31.

Valuation (modeled)modeled

Provath models Toltec Pharmaceuticals, Llc at approximately $125M (range $4.6M–$679M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.69× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era. Within the normal band (69% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 15.5 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 16.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 55% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 59% of those peers.

Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.